ASCO 2024 preview – two strikes against USP1
Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.
ASCO 2024 preview – new Car-T target shows liver cancer promise
Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.
ASCO 2024 preview – Merus’s home run remains unconfirmed
Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.
ASCO 2024 preview – more questions for BioNTech
Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.
ASCO 2024 preview – toxicity looms large for J&J
Four deaths cast doubt on J&J’s multi-pronged KLK2 push.
EHA 2024 preview – Novartis doubles up
The conference’s abstract drop features ASC4First in its plenary session.
Bolt’s setback didn’t come out of the blue
The company scraps its lead project and clears out its C-suite, but there was already a precedent.
